PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 1, 20260 citations

5'-ectonucleotidase (CD73) inhibitors: a patent review (2021-present).

View Full Paper
ZWZhaolin WangAJAnna K. Junker

Key Points

  • To review recent patents regarding CD73 inhibitors and their development as versatile therapeutic agents.
  • Analyzed patents from 2021 to present
  • Assessed trends in inhibitor development
  • Evaluated advancements in pharmacokinetics and bioavailability
  • Shift observed from maximizing potency to balanced optimization
  • Emergence of perorally bioavailable small molecules
  • Development of CD73-targeted imaging agents noted

Abstract

Recent patents indicate a shift from maximizing enzymatic potency toward balanced optimization of potency, pharmacokinetics, and combinatorial compatibility. Perorally bioavailable small molecules and CD73-targeted imaging agents are positioning CD73 inhibition as a mature and versatile therapeutic and theranostic strategy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/69a3d811ec16d51705d2e939https://doi.org/10.1080/13543776.2026.2638344
Ask AI
Helpful
Bookmark
Share
View Full Paper